<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36859">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959321</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801</org_study_id>
    <nct_id>NCT01959321</nct_id>
  </id_info>
  <brief_title>An Observational Study of Hepatitis C Virus in Pregnancy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center observational study examines risk factors for HCV transmission from mother
      to baby.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center observational study examines risk factors for HCV transmission from mother
      to baby. The study will also assess risk factors associated with Hepatitis C Virus (HCV)
      infection in pregnant women.  Also, the study will describe the outcomes of pregnant women
      with HCV as well as the outcomes of their infants to 18 months of age.

      Approximately 1,800 HCV antibody positive pregnant women and their infants will be followed
      from baseline until the infant is 18 months. A randomly selected control cohort of 3,600
      pregnant women who are HCV antibody negative will be followed until delivery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>HCV infection of the offspring</measure>
    <time_frame>at 2 months and/or 18 months of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is HCV infection of the offspring, where infection is defined by satisfying any one of the following criteria:
HCV RNA positive (i.e. presence of  viral load) by polymerase chain reaction (PCR) test at 2-6 months (2 month visit)
HCV RNA positive and HCV antibody positive at the 18-24 months (18 month visit)
HCV RNA positive at 18-24 months with a negative HCV antibody at 18-24 months and negative RNA at 2-6 months.  However, the positive result must be confirmed by a repeat test on the 18-month sample to qualify.
HCV antibody positive at 18-24 months with negative HCV RNA at both visits. However, the positive result must be confirmed by a repeat test on the 18-month sample to qualify.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery &lt; 37 weeks of gestation</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational diabetes mellitus (GDM)</measure>
    <time_frame>during pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal bleeding during pregnancy</measure>
    <time_frame>during pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>during pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholestasis</measure>
    <time_frame>during pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load in infant</measure>
    <time_frame>at birth, 2 months, and 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV antibody status in infant</measure>
    <time_frame>at 18 months of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>positive or negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight of infant</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperbilirubinemia</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak total bilirubin of at least 15 mg% or the use of phototherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit (NICU) admission</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as less than the 5th percentile birth weight for gestational age at birth, assessed specifically by sex and race of the infant based on United States birth certificate data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal infections</measure>
    <time_frame>at birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>sepsis and pneumonia</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Seropositive for Anti-HCV</arm_group_label>
    <description>Anti-HCV positive (includes seropositive viremic and seropositive non-viremic)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seronegative for Anti-HCV</arm_group_label>
    <description>Anti-HCV negative</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      maternal serum maternal plasma infant serum infant plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with singleton pregnancies presenting for prenatal care prior to 23 weeks, 6 days
        gestation at Maternal-Fetal Medicine Units (MFMU) Network hospital sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Singleton pregnancy

          2. An HCV antibody positive screen (case) OR a randomly selected HCV antibody negative
             screen (control) matched to a case patient by project gestational age (see below) +/-
             2 weeks and clinical center site.  HCV antibody screen will be measured using two
             FDA-approved ELISA tests,  the Abbott Architect version 3.0 system and the Ortho HCV
             3.0.

          3. Gestational age at screening no later than 236 weeks and gestational age at
             enrollment no later than 276 weeks, based on clinical information and evaluation of
             the earliest ultrasound as described below.

        Exclusion Criteria:

          1. Eligible for the Maternal-Fetal Medicine Units (MFMU) Network Cytomegalovirus (CMV)
             trial (positive CMV Immunoglobulin M (IgM) and Immunoglobulin G (IgG) with low
             avidity) or potentially eligible (positive IgM, negative IgG)

          2. Planned termination of pregnancy

          3. Known major fetal anomalies or demise

          4. Intention of the patient or the managing obstetricians for the delivery to be outside
             a MFMU Network center

          5. For the case cohort only: unwilling or unable to commit to 18 months of follow-up for
             HCV positive infants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uma Reddy, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth A Thom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Prasad, DO, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uma Reddy, MD</last_name>
    <phone>301-496-1074</phone>
    <email>uma.reddy@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Harris, BSN</last_name>
      <phone>205-996-6262</phone>
      <email>stacylharris@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan TN Tita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Kushniruk, RN, PhD</last_name>
      <phone>650-724-0395</phone>
      <email>karink1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Yasser El-Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Hale, RN BSN</last_name>
      <phone>303-724-6685</phone>
      <email>kathy.a.hale@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Gibbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Mallett, RN BSN CCRC</last_name>
      <phone>312-503-3200</phone>
      <email>g-mallett@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Alan M Peaceman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Bousleiman, RNC MSN MPH</last_name>
      <phone>212-305-4348</phone>
      <email>sb1080@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald J Wapner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Clark, RN</last_name>
      <phone>919-350-6117</phone>
      <email>kelly_clark@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Thorp, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy S Bishop, RNC MSN</last_name>
      <phone>919-668-7475</phone>
      <email>sincl008@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Geeta K Swamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Dalton, RNC</last_name>
      <phone>216-778-7533</phone>
      <email>wdalton@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Edward Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francee Johnson, BSN</last_name>
      <phone>614-293-5632</phone>
      <email>johnson.126@osu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francee Johnson, RN</last_name>
      <phone>614-293-5632</phone>
      <email>johnson.126@osu.edu</email>
    </contact>
    <investigator>
      <last_name>Jay D Iams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Allard, RNC</last_name>
      <phone>401-274-1122</phone>
      <email>dallard@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Dwight J Rouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Moseley, RN</last_name>
      <phone>214-648-2591</phone>
      <email>lisa.moseley@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Brian M Casey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Salazar, MSN</last_name>
      <phone>409-772-0312</phone>
      <email>assalaza@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>George R Saade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felecia Ortiz, RN BSN</last_name>
      <phone>713-500-6467</phone>
      <email>Felecia.Ortiz@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Baha Sibai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hill, RN</last_name>
      <phone>801-585-7645</phone>
      <email>Kim.Hill@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael W Varner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
